Atai Life Sciences 관리

관리 기준 확인 2/4

Atai Life Sciences CEO는 Srini Rao, Jun2024 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 1.73M, 31.7% 로 구성됩니다. 31.7% 급여 및 68.3% 보너스(회사 주식 및 옵션 포함). 는 € 170.57K 가치에 해당하는 회사 주식의 0.07% 직접 소유합니다. 170.57K. 경영진과 이사회의 평균 재임 기간은 각각 1.1 년과 3.8 년입니다.

주요 정보

Srini Rao

최고 경영자

US$1.7m

총 보상

CEO 급여 비율	31.7%
CEO 임기	less than a year
CEO 소유권	0.07%
경영진 평균 재임 기간	1.1yrs
이사회 평균 재임 기간	3.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Srini Rao 의 보수는 Atai Life Sciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$129m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$2m	US$550k	-US$40m
Sep 30 2023	n/a	n/a	-US$67m
Jun 30 2023	n/a	n/a	-US$145m
Mar 31 2023	n/a	n/a	-US$149m
Dec 31 2022	US$4m	US$550k	-US$152m
Sep 30 2022	n/a	n/a	-US$196m
Jun 30 2022	n/a	n/a	-US$194m
Mar 31 2022	n/a	n/a	-US$205m
Dec 31 2021	US$12m	US$481k	-US$168m
Sep 30 2021	n/a	n/a	-US$166m
Jun 30 2021	n/a	n/a	-US$218m
Mar 31 2021	n/a	n/a	-US$185m
Dec 31 2020	US$3m	US$400k	-US$170m

보상 대 시장: Srini 의 총 보상 ($USD 1.73M )은 German 시장( $USD 846.96K ).

보상과 수익: Srini 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Srini Rao (55 yo)

less than a year

테뉴어

US$1,734,650

보상

Dr. Srinivas G. Rao, M.D., Ph D., also known as Srini, serves as Co-Chief Executive Officer of Atai Life Sciences N.V. since June 01, 2024. He serves as Clinical Advisory Board Member at Bionomics Limited...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christian Angermayer	Founder & Chairman of the Supervisory Board	no data	US$158.96k	2.48% € 6.1m
Srinivas Rao	Co-Founder & Co-CEO	less than a year	US$1.73m	0.070% € 170.6k
Florian Brand	Co-Founder	6.4yrs	US$3.03m	0.20% € 483.2k
Anne Johnson	Chief Financial Officer	1.1yrs	US$1.17m	0.044% € 107.4k
Michael Raven	Senior Vice President of Operations	1.1yrs	데이터 없음	데이터 없음
Frank Stegert	Vice President of Investment & Venture Management	3.8yrs	데이터 없음	데이터 없음
Ryan Barrett	Senior VP	3.8yrs	데이터 없음	데이터 없음
Glenn Short	Senior Vice President of Early Development	1.1yrs	데이터 없음	데이터 없음
Sahil Kirpekar	Chief Business Officer	2yrs	데이터 없음	0.038% € 93.7k
Kevin Craig	Senior Vice President of Clinical Development	1.1yrs	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

43yo

평균 연령

경험이 풍부한 관리: 9VC 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christian Angermayer	Founder & Chairman of the Supervisory Board	3.8yrs	US$158.96k	2.48% € 6.1m
Sabrina Johnson	Independent Member of Supervisory Board	3.8yrs	US$151.96k	0% € 0
Laurent Fischer	Independent Supervisory Director	less than a year	데이터 없음	데이터 없음
Amir Kalali	Independent Member of Supervisory Board	3.8yrs	US$140.46k	0.0028% € 6.8k
Scott Braunstein	Independent Supervisory Director	less than a year	데이터 없음	데이터 없음
Andrea Smiley	Independent Member of Supervisory Board	3.8yrs	US$150.46k	0.0028% € 6.8k
Michael B. Auerbach	Independent Lead Member of Supervisory Board	3.8yrs	US$158.96k	0.31% € 765.3k

3.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 9VC 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.

Atai Life Sciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Atai Life Sciences N.V. Announces Board and Supervisory Board Changes

Co-Founder recently sold €267k worth of stock

Atai Life Sciences N.V. Announces CEO Changes

Atai Life Sciences N.V., Annual General Meeting, May 17, 2024

Co-Founder & Chief Scientific Officer recently sold €106k worth of stock

atai Life Sciences Announces Management Changes

Recent updates

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$0.28 profit in 3Q 2023)

New major risk - Share price stability

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$0.21 loss in 2Q 2023)

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Bccal Film DMT)

New major risk - Financial position

Atai Life Sciences Announces Update on Beckley Psytech’S Phase 1/2A Trial of Ele-101 (Iv Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2A

Atai Life Sciences N.V. Announces Board and Supervisory Board Changes

Co-Founder recently sold €267k worth of stock

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.21 loss in 1Q 2023)

Atai Life Sciences N.V. Announces CEO Changes

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression

Atai Life Sciences N.V., Annual General Meeting, May 17, 2024

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Co-Founder & Chief Scientific Officer recently sold €106k worth of stock

Full year 2023 earnings released: US$0.25 loss per share (vs US$0.98 loss in FY 2022)

atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

atai Life Sciences Announces Management Changes

Atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)

Third quarter 2023 earnings released: EPS: US$0.28 (vs US$0.22 loss in 3Q 2022)

Atai Life Sciences N.V. (NasdaqGM:ATAI) acquired remaining stake of DemeRx IB, Inc.

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V. Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants

Co-Founder & CEO recently bought €54k worth of stock

atai Life Sciences Announces Results from the Phase 1 Iv-To-Subcutaneous Bridging Study of Pcn-101 (R-Ketamine)

Co-founder & CEO recently bought €96k worth of stock

Full year 2022 earnings released: US$0.98 loss per share (vs US$1.21 loss in FY 2021)

Atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of Grx-917

Atai Life Sciences Announces Results from Phase 2A Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

598 Initiates Phase 2B Proof-Of-Concept Trial of Rl-007 for Cognitive Impairment Associated with Schizophrenia

Atai Life Sciences Appoints Sahil V. Kirpekar as Chief Business Officer

Atai Life Sciences N.V. and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

Alexis De Rosnay Resigns as a Member of the Supervisory Board of Directors of Atai Life Sciences N.V

Atai Life Sciences N.V. to Report Q3, 2022 Results on Nov 10, 2022

Atai Life Sciences and Perception Neuroscience Completes Enrollment for Phase 2A Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

Atai Life Sciences N.V. Announces Initiation of Phase 1 Proof-Of-Concept Clinical Trial for Its Sol-Gel Based Direct-To-Brain Drug Delivery Technology

Atai Life Sciences N.V. Appoints Stephen Bardin as Managing Director

Atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and Iv Vls-01, A Synthetic Form of Dmt

atai Life Sciences N.V. Announces Initiation of Phase 1 Trial for Its MDMA Derivative, EMP-01

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.37 loss in 2Q 2021)

Atai Life Sciences N.V. to Report Q2, 2022 Results on Aug 15, 2022

Atai Life Sciences N.V. Announces Executive Changes

Atai Life Sciences N.V. to Report Q1, 2022 Results on May 16, 2022

Atai Life Sciences N.V., Annual General Meeting, May 25, 2022

atai Life Sciences N.V. Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments

Atai Life Sciences Announces Fda Investigational New Drug Clearance for Pcn-101 R-Ketamine Program

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia

Atai Life Sciences N.V. Announces the Launch of TryptageniX

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령